Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer The U.K.s NICE issued preliminary draft guidance recommending against the use of Lynparza olaparib from AstraZeneca for maintenance treatment of ovarian…

    Published on 7/27/2015
  • Clinigen Group, Clovis sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Business: Cancer Clinigen launched a European global access program for Clovis rociletinib to treat advanced non-…

    Published on 7/27/2015
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Gilead narrowed the eligibility criteria for Support Path, its patient access program for HCV treatments Sovaldi sofosbuvir and Harvoni …

    Published on 7/27/2015
  • Novacyt, Leica Biosystems sales and marketing update

    Novacyt S.A. (Euronext:ALNOV), Velizy-Villacoublay, France Leica Biosystems Inc., Nussloch, Germany Business: Diagnostic Novacyt and Leica launched NOVAprep liquid-based cytology screening platform in China for cancer …

    Published on 7/27/2015
  • Novocure sales and marketing update

    Novocure Ltd., Isle of Jersey Business: Cancer Novocure launched Optune tumor treating fields (TTFields) delivery device in Japan to treat recurrent glioblastoma multiforme (GBM). Optune is a non-invasive portable …

    Published on 7/27/2015
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Sanofi said it reached an agreement with NHS England to again make Jevtana cabazitaxel for prostate cancer available on the NHS. NHS England delisted the …

    Published on 7/27/2015
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic Takeda launched once-weekly oral Zafatek trelagliptin in Japan to treat Type II diabetes. The Japanese National Health Insurance (…

    Published on 7/27/2015
  • Alkermes, Otsuka Pharmaceutical sales and marketing update

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Neurology Otsuka filed a Citizens Petition with FDA asking the agency to deny or delay approval of an NDA for …

    Published on 7/20/2015
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The German Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that added benefit cannot be derived for Otezla …

    Published on 7/20/2015
  • Eisai, Eli Lilly, Novartis sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer NHS England will remove from its Cancer Drugs Fund (CDF) …

    Published on 7/20/2015
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious The German Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that a hint of non-quantifiable added …

    Published on 7/20/2015
  • Regeneron, Bayer sales and marketing update

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Ophthalmic Germanys Institute for Quality and Efficiency in Healthcare (IQWiG) said in a dossier …

    Published on 7/20/2015
  • Biodesix, UnitedHealth Group sales and marketing update

    Biodesix Inc., Boulder, Colo. UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. Business: Pharmacogenetics UnitedHealths United Healthcare unit issued a positive coverage decision for Biodesixs VeriStrat, a blood-…

    Published on 7/13/2015
  • Bristol-Myers, Ono Pharmaceutical sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer Opdivo nivolumab will be offered under the U.K.s Early Access to Medicine Scheme (EAMS) to …

    Published on 7/13/2015
  • Cepheid sales and marketing update

    Cepheid Inc. (NASDAQ:CPHD), Sunnyvale, Calif. Business: Diagnostic Xpert Ebola Test was added to the World Health Organizations (WHO) list of Ebola diagnostics eligible for procurement. Xpert is a rapid in vitro …

    Published on 7/13/2015
  • Clinigen Group, Pharming sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Business: Inflammation The companies, along with patient organization HAEi (Skanderborg, Denmark), …

    Published on 7/13/2015
  • Commonwealth Laboratories sales and marketing update

    Commonwealth Laboratories Inc., Salem, Mass. Business: Diagnostic Commonwealth launched its IBSchek ELISA-based blood test to diagnose irritable bowel syndrome (IBS). The laboratory-developed test (LDT) detects …

    Published on 7/13/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisai launched Lenvima lenvatinib in Japan to treat unresectable thyroid cancer. The recommended dose for the inhibitor of multiple VEGF receptor tyrosine …

    Published on 7/13/2015
  • EKF Diagnostics, Greenville Health System sales and marketing update

    EKF Diagnostics Holdings plc (LSE:EKF), Penarth, U.K. Greenville Health System, Greenville, S.C. Business: Pharmacogenetics EKFs subsidiary Selah Genomics launched the PrecisionPath Colon test in the U.S., excluding New…

    Published on 7/13/2015
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Cancer The U.K.s NICE issued preliminary draft guidance recommending against the use of Gileads Zydelig idelalisib to treat adults with untreated chronic…

    Published on 7/13/2015
  • Kyorin sales and marketing update

    Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Pulmonary Kyorin launched Eklira Genuair aclidinium bromide in Japan to treat chronic obstructive pulmonary disease (COPD). The recommended dosage is …

    Published on 7/13/2015
  • Kythera sales and marketing update

    Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH), Calabasas, Calif. Business: Dermatology Kythera launched Kybella deoxycholic acid in the U.S. to reduce submental (under chin) fat. The drug is a synthetic sodium …

    Published on 7/13/2015
  • LabCorp sales and marketing update

    Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostic LabCorp launched HCV NS5A and NS5B HCV drug resistance assays to evaluate resistance to HCV drugs Harvoni ledipasvir and Sovaldi …

    Published on 7/13/2015
  • Meridian Bioscience sales and marketing update

    Meridian Bioscience Inc. (NASDAQ:VIVO), Cincinnati, Ohio Business: Diagnostic Meridian received CE Mark approval and launched its molecular assays in the EU to detect herpes simplex virus type 1 (HSV-1) and HSV-2. The …

    Published on 7/13/2015
  • Newron, Zambon Co. S.p.A sales and marketing update

    Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Zambon Co. S.p.A, Bresso, Italy Business: Neurology Zambon launched Xadago safinamide in Germany to treat mid- to late-stage Parkinsons disease (PD). Zambon has …

    Published on 7/13/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993